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West Nile virus (WNV) is an emerging mosquito-borne pathogen that was reported for the
first time in the Western hemisphere in August 1999, when an encephalitis outbreak in New
York City resulted in 62 clinical cases and 7 deaths. WNV, for which no antiviral therapy has
been described, was recently recovered from a pool of mosquitoes collected in New York City.
In anticipation of the recurrence of WNV during the summer of 2000, an analysis was made
of the efficacy of the nucleoside analogue ribavirin, a broad-spectrum antiviral compound
with activity against several RNA viruses, for treatment of WNV infection. High doses of
ribavirin were found to inhibit WNV replication and cytopathogenicity in human neural cells
in vitro.
The Flaviviridae, a family of enveloped positive-strand RNA
viruses, include West Nile virus (WNV), as well as other sig-
nificant human pathogens, such as hepatitis C, yellow fever,
dengue, Japanese encephalitis, and St. Louis encephalitis vi-
ruses [1]. Whereas hepatitis C virus (genus Hepacivirus) may
be transmitted by blood products or sexual activity, most mem-
bers of the Flavivirus genus, including WNV, are transmitted
by arthropods [1]. After an incubation period of 3–6 days,
WNV infections typically result in subclinical or nonspecific,
mild febrile illnesses lasting 3–5 days [2]. Host factors, including
age and immune status, influence pathogenesis. Elderly indi-
viduals are at higher risk of progressing to fatal neurological
disease, involving profound motor weakness and axonal neu-
ropathy [3]. WNV is endemic in parts of Africa, Europe, the
Middle East, and Asia [2], and it has potential to cause large
epidemics in populations where background immunity is low.
The largest African epidemic occurred in 1974 in the Cape
province, South Africa, with 3000 clinical cases diagnosed after
unusually heavy rainfalls; a large outbreak in Romania in 1996
resulted in 352 acute infections of the central nervous system,
with a case-fatality rate of ∼4% [2]. WNV was recognized for
the first time in the Americas in August 1999, when an outbreak
in New York City resulted in 62 cases of acute encephalitis.
Seven patients died, and mortality among horses and birds was
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substantial [3]. Genetic analysis of the envelope protein se-
quence indicated that the viral strain most closely resembled
an isolate from a goose in Israel in 1998, demonstrating the
wide geographic distribution of this emerging pathogen [4, 5].
Antiviral therapy for hepatitis C has been described [6]; how-
ever, no specific treatment has been reported for WNV or other
flavivirus infections. We recently reported that the presence of
WNV RNA in cerebrospinal fluid may be associated with poor
clinical outcome [7]. These findings, together with indications
that WNV has persisted in mosquitoes in New York City during
the winter [8], emphasize the importance of rapid diagnosis of
WNV infections and of establishing antiviral treatment. We
therefore tested a panel of nucleoside analogues for antiviral
activity against WNV.
Materials and Methods
Cells and virus. Human oligodendroglial (OL) cells [9] were
cultured in a humidified atmosphere at 377C, 5% CO2 in Dulbecco’s
modified Eagle medium/high glucose (DMEM; Irvine Scientific,
Santa Ana, CA) supplemented with 10% heat-inactivated fetal calf
serum (FCS), 2 mM glutamine, 100 U/mL penicillin, and 100 mg/
mL streptomycin. Aedes albopictus C6/36 cells were cultured at
257C in Leibovitz’s L-15 medium (Gibco-BRL, Gaithersburg, MD)
supplemented with 10% heat-inactivated FCS, 10% tryptose phos-
phate broth (Gibco-BRL), 100 U/mL penicillin, and 100 mg/mL
streptomycin. Virus was recovered after DMRIE-C (Gibco-BRL)
liposome-mediated transfection of WNV-NY1999 RNA into
OL cells. Virus-maintenance medium was a 1:1 mixture of sup-
plemented DMEM and OPTI-MEM I reduced-serum medium
(Gibco-BRL) resulting in 5% final serum concentration. Virus was
passaged only once in either OL or C6/36 cells after recovery by
RNA transfection; virus stocks were prepared as clarified OL cul-
JID 2000;182 (October) Ribavirin Inhibits WNV Replication 1215
ture supernatant when ∼80% of the cells had cytopathic effect or
as C6/36 culture supernatant 4 days after infection with the initial
OL virus isolate. Plaque-forming units were determined on con-
fluent OL cell layers by serial dilution of viral stock in duplicates
after overlay with 1% low-melting agarose in DMEM.
Antiviral drug evaluation. Nucleoside analogues (3-deazaguan-
ine; ICN 10169; ICN 10776; ICN 15100; 2′,3′-dideoxyinosine; ri-
bavirin; ribavirin analogues ICN 17261 and ICN 17377; FTC
[b-L-2′,3′-dideoxy-5-fluoro-3′-thiacytidine]; and pyrazofurin) were
provided by ICN Pharmaceuticals (Costa Mesa, CA). The drugs
were dissolved in dimethyl sulfoxide to 100 mM and in OPTI-
MEM to working concentrations. Two hours before treatment with
drug at various concentrations, OL cells were seeded in virus-main-
tenance medium to 80% confluence on microtiter plates and were
infected at a multiplicity of 0.1. Half the wells of each plate were
treated with drug but not infected. After 3 days, 50 mL of super-
natant were transferred onto fresh microtiter plates for cytotoxicity
assays (release of lactate dehydrogenase from lysed cells; CytoTox
96; Promega, Madison, WI); 50 mL of supernatant was extracted
with 150 mL Tri-Reagent LS (Molecular Research, Cincinnati, OH)
for real-time reverse transcriptase (RT)–polymerase chain reaction
(PCR) analysis [7], using diagnostic primers directed against the
NS5 region; the remaining 100 mL of supernatant and the under-
lying cell layer were supplemented with XTT labeling mix to assay
cell proliferation (mitochondrial metabolism of XTT tetrazolium
salt; Roche, Basel, Switzerland). The cytotoxicity and cell prolif-
eration assays were measured with a vmax plate reader (Molecular
Devices, Sunnyvale, CA) at 490 nm, with 650 nm as reference
wavelength.
Results
A panel of 10 nucleoside analogues was screened for antiviral
activity in WNV-NY1999–infected human OL cells at 20 mM
concentrations. This initial screening was performed by size
fractionation and Northern blot analysis of total RNA fol-
lowed by hybridization with probes against the NS5 poly-
merase gene and host-cell glyceraldehyde-3-phosphate-dehy-
drogenase (GAPDH) as reference (data not shown). Two
compounds, pyrazofurin and ribavirin, had antiviral activity.
Pyrazofurin affects activity of orotate monophosphate decar-
boxylase in pyrimidine biosynthesis. Because of its high cyto-
toxicity, pyrazofurin was not tested further. However, the drug’s
ability to reduce WNV genomic RNA to levels !1% of
GAPDH-normalized infected untreated control values suggests
that further drug screening using less toxic derivatives may be
useful.
For a detailed evaluation of the activity of ribavirin, we mea-
sured 3 parameters (figure 1): (1) cell lysis due to cytopathic
effect and drug-induced cytotoxicity was measured via the re-
lease of a stable cytoplasmic enzyme (lactate dehydrogenase)
into the culture supernatant; (2) viral replication was measured
with real-time PCR, using diagnostic primers that amplified a
69-bp fragment from the NS5 region, detected by a linear
fluorochrome/quencher probe annealing within that region; and
(3) inhibition of cellular proliferation and viability due to in-
fection or drug side effects was measured at the end of treatment
by mitochondrial metabolic activity.
Ribavirin reduced extracellular WNV RNA by ∼50% at 60-
mM (ED50) and by ∼90% at 190-mM (ED90) concentrations (figure
1A); the reference value of 100% extracellular viral RNA was
determined by real-time RT-PCR, using RNA isolated from the
supernatant of infected untreated cells. At the ED50 and ED90
concentrations, cytopathogenicity decreased from 90% to 20%
of the reference value obtained with infected untreated controls
(figure 1A). Cell proliferation of infected untreated cells was
∼55% of the noninfected untreated controls, and it recovered to
95% at 200 mM ribavirin (figure 1A, 1C). The titer of WNV was
reduced by 4 orders of magnitude (from 107 to 103 pfu/mL) in
the presence of 200 mM ribavirin (figure 1D). The greater re-
duction in plaque-forming units than in extracellular viral RNA
at 200 mM ribavirin suggests that not all RNA measured by RT-
PCR is present as infectious units. In noninfected cells, ribavirin
did not inhibit cell growth or produce cytotoxic effects at con-
centrations as high as 400 mM (figure 1B). All studies were per-
formed in duplicate. Results were similar for virus stocks gen-
erated on OL or C6/36 cells and for 2 batches of ribavirin. On
the basis of these experiments, we estimate that ribavirin has an
in vitro selectivity index of ∼7.
Discussion
Ribavirin is a guanosine analogue with in vitro antiviral ac-
tivity against a broad spectrum of RNA and DNA viruses,
including members of the Arenaviridae, Bunyaviridae, Flavi-
viridae, Herpesviridae, Orthomyxoviridae, Paramoyxoviridae,
and Bornaviridae families. Within the Flaviviridae, in vitro ac-
tivity has been demonstrated for yellow fever, dengue types 1–4,
banzi, Japanese encephalitis [10, 11], and hepatitis C viruses.
Ribavirin has been used to treat human patients infected with
respiratory syncytial [12], Lassa [13], Hantaan [14], La Crosse
[15], and (in combination with interferon-a) hepatitis C [6] vi-
ruses. Ribavirin is phosphorylated by cellular enzymes and is
postulated to exert antiviral effects by several mechanisms: (1)
depletion of the intracellular GTP pool by interference with
host-cell inosine monophosphate (IMP) dehydrogenase, the en-
zyme that converts IMP to xanthosine monophosphate, a pre-
cursor molecule in the biosynthesis of GTP and dGTP; (2)
interference with mRNA capping guanylylation; (3) specific in-
hibition of some viral polymerases; and (4) enhancement of the
Th1 antiviral immune response [11, 16].
After oral administration, ribavirin concentrations in cere-
brospinal fluid are ∼70% of those in serum [17]. We are not
aware of published data concerning levels of ribavirin in the
brain after intravenous administration; however, on the basis
of results from the intravenous 7-day regimens employed for
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Figure 1. Concentration-dependent effect of ribavirin on viral replication, cell proliferation, and cytopathogenicity in oligodendroglial (OL)
cells. Two hours before treatment with ribavirin at various concentrations, cells were infected with WNV-NY1999 at a multiplicity of 0.1. Cells
were assayed 3 days later for host cell proliferation (v), cytopathogenicity (m), and amount of viral RNA in the culture supernatant (m; A).
Noninfected cells were assayed in parallel for cell proliferation (V) and drug-induced cytotoxic effect (M; B). Results are expressed as percentage
of control values. One hundred percent cellular proliferation values were obtained from untreated uninfected cells. One hundred percent viral
replication and cytopathogenicity values were obtained from untreated infected cells. Reduction of cytopathogenicity (magnification, 3200; C)
and virus load (plaque-forming units per millimeter; D) after 3 days treatment with 200 mM ribavirin are also shown.
treatment of La Crosse encephalitis and Hantaan fever with a
loading dose of 25–33 mg/kg of body weight followed by 24–64
mg/kg of body weight per day administered intravenously [14,
15], we extrapolate that intravenous administration of ribavirin
will probably result in ∼100 mM concentrations in the cerebro-
spinal fluid. This concentration exceeds our measured ED50 of
60 mM for reduction of extracellular viral RNA. Although a
higher concentration of ribavirin in cerebrospinal fluid may be
more desirable, the efficacy:benefit ratio will be revealed only
through clinical studies. It is important to note that reversible
hemolytic anemia can occur at these doses and may require
transfusion [18].
One pool of mosquitoes collected in New York City in Feb-
ruary 2000 yielded live WNV [8], indicating that this emerging
pathogen has established its presence in the Western hemi-
sphere. WNV is not yet endemic in the Americas, and the short
period since its introduction, in August 1999, may aggravate
outbreaks until background immunity has developed in the
human and peridomestic animal population. It is clearly im-
portant to identify drugs for treatment of WNV that will have
better selectivity and therapeutic indices than ribavirin. Fur-
thermore, the efficacy of ribavirin in animal models of WNV
encephalitis remains to be addressed. Nonetheless, our findings
suggest that ribavirin at high doses may improve prognosis in
individuals with WNV encephalitis.
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